Pharmacokinetics and Pharmacodynamics of Recombinant Human EPO-Fc Fusion Protein In Vivo

Shi, Xunlong; Yang, Jianjun; Zhu, Haiyan; Ye, Li; Feng, Meiqing; Li, Jiyang; Huang, Hai; Tao, Qun; Ye, Dan; Sun, Lee-Hwei K.; Sun, Bill N. C.; Sun, Cecily R. Y.; Han, Guizhen; Liu, Yuanyuan; Yao, Minghui; Zhou, Pei; Ju, Dianwen
August 2013
PLoS ONE;Aug2013, Vol. 8 Issue 8, p1
Academic Journal
In this study, the in vivo pharmacokinetics and pharmacodynamics of a novel recombinant human erythropoietin (rhEPO) Fc fusion protein, rhEPO-Fc, were studied in both rodents and rhesus monkeys. Animal models of anemia induced by irradiation, cyclophosphamide and partial renal ablation were used to evaluate therapeutic effects of rhEPO-Fc. We have demonstrated that serum half-life of rhEPO-Fc was 29.5 to 38.9 h at doses of 8, 25, 80 µg/kg in rhesus monkeys and 35.5 to 43.5 h at doses of 16, 50, 160 µg/kg in rats. In anemia animal models, rhEPO-Fc dose-dependently (7.5–30.0 µg/kg in mice, 5.4–21.4 µg/kg in rats and 5.0–10.0 µg/kg in rhesus monkeys) increased reticulocyte level, followed by an increase of RBC count, hemoglobin and hematocrit levels. At reduced intervention frequency of weekly treatments, rhEPO-Fc showed similar hematopoietic effects as compared with rhEPO given three times a week. These results indicated that rhEPO-Fc could potentially be used in treatment of anemia and warrants future clinical trials.


Related Articles

  • International Nonproprietary Names. Haselbeck, Anton // WHO Drug Information;2010, Vol. 24 Issue 1, p21 

    The article discusses the biochemical properties of epoetins, which are recombinant versions of human erythropoietin. The carbohydrate structure and glycosylation process of epoetins are described. All epoetins irrespective of their International Nonproprietary Name (INN) exhibit distinct...

  • Erythropoiesis stimulating agents: approaches to modulate activity. Sinclair, Angus M. // Biologics: Targets & Therapy;2013, Vol. 7, p161 

    Recombinant human erythropoietin (rHuEPO), such as the approved agents epoetin alfa and epoetin beta, has been used successfully for over 20 years to treat anemia in millions of patients. However, due to the relatively short half-life of the molecule (approximately 8 hours), frequent dosing may...

  • Erythropoietin reduces neuronal cell death and hyperalgesia induced by peripheral inflammatory pain in neonatal rats.  // Molecular Pain;2011, Vol. 7 Issue 1, p51 

    The article reports on the research conducted on rats to study the effect of pain in brain development during neonatal stage. It states that the rats react in the inflammatory pain which is essential for the study of therapies for infants. It also informs that recombinant human erythropoietin...

  • Pharmacokinetic-Pharmacodynamic Modelling of Recombinant Human Erythropoietin in Athletes: A Population Approach. Gaudard, A. GaudardA.; Varlet-Marie, E.; Audran, M.; Gomeni, R.; Bressolle, F. // Clinical Drug Investigation;2003, Vol. 23 Issue 3, p167 

    Objective: To develop a pharmacokinetic model able to take into account the negative feedback loop of endogenous erythropoietin production observed after repeated administration of recombinant human erythropoietin (rHuEPO), and to propose a pharmacokinetic-pharmacodynamic model capable of...

  • Pharmacokinetics/Pharmacodynamics of Recombinant Human Erythropoietins in Doping Control. Varlet-Marie, Emmanuelle; Gaudard, Aurélie; Audran, Michel; Bressolle, Francoise // Sports Medicine;2003, Vol. 33 Issue 4, p301 

    The purpose of this paper is: (i) to compare recombinant human erythropoietin (rHuEPO) pharmacokinetics in athletes and healthy individuals; and (ii) to report pharmacokinetic/pharmacodynamic (PK/PD) studies performed in athletes. Effect parameters in PK/PD studies included: (i) red blood cell...

  • Recombinant Human Coagulation Factor IX Fc Fusion Protein Effective in Kids B-LONG Study. Cunningham, Muriel; Fischer, Kathelijn // MD Conference Express;Aug2015, Vol. 15 Issue 21, p6 

    The Kids B-LONG study was conducted to evaluate the pharmacokinetics, safety, and efficacy of recombinant human coagulation factor IX Fc fusion protein (rFIXFc) in pediatric subjects with hemophilia B. rFIXFc is considered safe and efficacious for prophylaxis and the control of acute bleeding in...

  • Pharmacokinetics, Pharmacodynamics, and Tolerability of Single Ascending Doses of RCT-18 in Chinese Patients with Rheumatoid Arthritis. Chen, Xia; Hou, Yong; Jiang, Ji; Zhao, Qian; Zhong, Wen; Wang, Wenxiang; Yao, Xuejing; Li, Lin; Fang, Jianmin; Zhang, Fengchun; Hu, Pei // Clinical Pharmacokinetics;Nov2014, Vol. 53 Issue 11, p1033 

    Background and objectives: RCT-18 is a novel recombinant fusion protein that targets and neutralizes B-lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL). This first in-human study investigated the safety, tolerability, pharmacokinetics, immunogenicity, and pharmacodynamics...

  • Melatonin ameliorates oxidative stress and reproductive toxicity induced by cyclophosphamide in male mice. Chabra, A; Shokrzadeh, M; Naghshvar, F; Salehi, F; Ahmadi, A // Human & Experimental Toxicology;Feb2014, Vol. 33 Issue 2, p185 

    The present study evaluated the efficacy of melatonin in cyclophosphamide (CP)-induced testicular injury, lipid peroxidative damage, and antioxidant enzymes status of the mice testis on the basis of biochemical and histological studies. Mice were pretreated with four different doses of melatonin...

  • EMEA Guidelines on Biosimilars and Their Clinical Implications. Rossert, Jerome // Kidney & Blood Pressure Research;Jul2007, Vol. 30 Issue S1, p13 

    The article summarizes the guidelines on recombinant human erythropoietin issued by the European Agency for the Evaluation of Medicinal Products and their implications. Various studies on recombinant human erythropoietin still need to be conducted, including human pharmacokinetic and...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics